About APVO455: Advancing Nectin-4 T-cell Targeting in Solid Tumors APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and ...

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers Provided by ACCESS Newswire Jun 20, 2025, 5:55:00 AM ...

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers ACCESS Newswire - Fri Jun 20, 3:55AM CDT ...

DHS issued a terrorism bulletin with experts warning of Iranian sleeper cells, campus protest infiltration and online radicalization tactics after U.S. strikes on nuclear sites.

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

Health A lifesaving gift: Son donates stem cells after father’s cancer diagnosis When Steve Howard was diagnosed with a blood cancer, his son, Jake, was the best match for a donation.

Innate immune cells articles from across Nature Portfolio Atom RSS Feed Innate immune cells are white blood cells that mediate innate immunity and include basophils, dendritic cells, eosinophils ...

Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.

In the inflamed mucosa of active UC and CD patients, IL-17 expression was clearly detectable in CD3+ T cells or CD68+ monocytes/macrophages. The average number of IL-17+ cells was significantly ...